Skip to main content
SpringerLink
Log in

Prevention of the “no reflow” phenomenon in the canine heart by mioflazine

  • Original Contributions
  • Published:
Basic Research in Cardiology Aims and scope Submit manuscript

Summary

The effects of oral pretreatment with mioflazine (2.5 mg·kg−1) on regional myocardial reflow, infarct size reduction and hemodynamic recovery were studied in 24 anesthetized open-chest dogs undergoing 90 minutes of acute left anterior descending coronary artery (LAD) occlusion followed by 150 minutes of reperfusion.

Regional myocardial blood flow was measured with tracer microspheres, and infarct size was determined by triphenyl tetrazolium chloride staining. Pretreatment with mioflazine resulted in a reduced diastolic aortic pressure (p<0.05) and an elevated cardiac output and LV dpdt max (p<0.05). These effects persisted throughout the experiment. In control animals (n=12) a hyperemic reflow response was found in the perfusion area of the LAD during the first minutes of reperfusion. After 150 min of reperfusion, however, the viable myocardium of the LAD area became underperfused, and almost no reflow was found in the infarcted zones.

In the animals pretreated with mioflazine (n=12) the hyperemic response persisted throughout the reperfusion phase and the no-reflow phenomenon was prevented. Infarct size (expressed as percentage of perfusion area) tended to be smaller in this group: 23.7±12.4% versus 33.7±19.2% (p>0.05).

Left atrial pressure increased during LAD occlusion in both groups but normalized completely in the drug-pretreated animals (p<0.05).

It is concluded that pretreatment with mioflazine prevents the no-reflow phenomenon after reperfusion of an evolving infarction, tends to reduce infarct size and improves hemodynamic recovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meyer J, Merx W, Schmitz H, Erbel R, Kiesslich T, Dorr R, Lambertz H, Beithge C, Krebs W, Bardos P, Minale C, Messmer BJ, Effert S (1982) Percutaneous transluminal coronary angioplasty immediately after inter-coronary streptolysis of transmural myocardial infarction. Circulation 66 (Suppl 5):905–916

    PubMed  Google Scholar 

  2. Philips SJ, Kongtahworn C, Skinner JR, Zeff RH (1983) Emergency coronary artery reperfusion: A choice therapy for evolving myocardial infarction. J Thorac Cardiovasc Surg 86:679–688

    PubMed  Google Scholar 

  3. Maroko PR, Libly P, Finks WR, Bloor CM, Shell WE, Sobel BE, Ross J Jr (1972) Coronary artery reperfusion I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 51:2710–2716

    PubMed  Google Scholar 

  4. Geary GG, Smith GT, McNamara JJ (1982) Quantitative effect of early coronary artery reperfusion in baboons. Extent of salvage of the perfusion bed of an occluded artery. Circulation 66:391–396

    PubMed  Google Scholar 

  5. Lang TW, Corday E, Gold H, Meerbaum S, Rubins S, Constantin C, Hirose S, Osher J, Rosen V (1974) Consequences of reperfusion after coronary occlusion. Effects of hemodynamics and regional myocardial metabolic function. Am J Cardiol 33:69–81

    Article  PubMed  Google Scholar 

  6. Bresnahan GR, Roberts R, Shell WE, Ross J Jr, Sobel BE (1974) Deleterious effects due to hemorrhage after myocardial infarction. Am J Cardiol 33:82–86

    PubMed  Google Scholar 

  7. Majro G, Ames A, Chiang J, Wright RL (1967) No reflow after cerebral ischemia. Lancet 2:569–570

    Article  Google Scholar 

  8. Summers WK, Janison RL (1971) The no reflow phenomenon in renal ischemia. Lab Invest 25:635–643

    PubMed  Google Scholar 

  9. Kloner RA, Ganote CE, Jennings RB (1974) The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54:1496–1508

    PubMed  Google Scholar 

  10. Kloner RA, Ganote CE, Whalen DA Jr, Jennings RB (1974) Effects of transient periods of ischemia on myocardial cells. Fine structure during the first few minutes of reflow. Am J Pathol 74:399

    PubMed  Google Scholar 

  11. Leaf A (1973) Cell swelling: A factor in ischemic tissue injury. Circulation 48:455–458

    PubMed  Google Scholar 

  12. Cobb FR, McHale PA, Rembert JC (1978) Effects of acute cellular injury on coronary vascular reactivity in awake dogs. Circulation 57:962–968

    PubMed  Google Scholar 

  13. Hellstrom HR (1971) Coronary artery stasis after induced myocardial infarctions in the dog. Cardiovasc Res 5:371

    PubMed  Google Scholar 

  14. Flameng W, Daenen W, Borgers M, Thoné F, Xhonneux R, Van de Water A, Van Belle H (1981) Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemia. Circulation 64:796–807

    PubMed  Google Scholar 

  15. Flameng W, Xhonneux R, Van Belle H, Borgers M, Van de Water A, Wynants J, Thoné F, Van Daele P, Janssen P (in press) Cardioprotective effects of mioflazine during one hour normothermic global ischemia in the canine heart. Cardiovasc Res

  16. Van Belle H, Xhonneux R, Borgers M, Flameng W (1983) Cardioprotective effects of adenosine, lidoflazine and R51469. In: Berne RM, Rall TW, Rubio R (eds) Regulatory functions of adenosine. Martinus Nyhoff Publishers

  17. Schaper W, Flameng W, Winkler B, Neugebauer G, Carl M, Pasyk S (1976) Quantification of collateral resistance in acute and chronic experimental coronary occlusion in the dog. Circ Res 39:371–377

    PubMed  Google Scholar 

  18. Grayson JW, Irvine M, Parratt JR, Cunningham J (1968) Vasospastic elements in myocardial infarction following coronary occlusion in the dog. Cardiovasc Res 2:54

    PubMed  Google Scholar 

  19. Flameng W: unpublished results

  20. Willerson JT, Watson JT, Hutton I, Templeton GH, Fixler D (1975) Reduced myocardial reflow in increased coronary vascular resistance following myocardial ischemia in the dog. Circ Res 36:771–781

    PubMed  Google Scholar 

  21. Humphrey SM, Seelye RN, Gavin JB (1982) The influence of adenosine on the no reflow phenomenon in anoxic and ischaemic hearts. Pharmacology 14:129–133

    Google Scholar 

  22. Humphrey SM, Seelye RN (1982) Improved functional recovery of ischemic myocardium by suppression of adenosine catabolism. J Thorac Cardiovasc Surg 84:16–22

    PubMed  Google Scholar 

  23. Van Belle H (1970) The disappearance of adenosine in dog blood after low oral doses of lidoflazine (0.31–5 mg/kg). Europ J Pharm 10:290–292

    Article  Google Scholar 

  24. Spieckermann PG, Fuchs C, Gehtmann JW, Knoll D, Kübler W, Bretschneider HJ (1972) Einfluß des Koronardilatators Lidoflazine auf den Adenosinstoffwechsel des Myocards während Ischämie und Anoxie. Arzneim Forsch (Drug Res) 22:1869–1874

    Google Scholar 

  25. Jageneau AHM, Schaper WKA, Van Gerven W (1969) Enhancement of coronary reactive hyperemia in unanaesthetized pigs by an adenosine-potentiator (lidoflazine). Naunyn-Schmiedebergs Arch Pharmak 265:16–23

    Article  Google Scholar 

Download references

Author information

Author notes

  1. R. Xhonneux

    Present address: Laboratories of Experimental Cardiovascular Surgery and Cardiology, K. University Leuven and Janssen Pharmaceutica, B-2340, Beerse, (Belgium)

Authors and Affiliations

  1. Laboratories of Experimental Cardiovascular Surgery and Cardiology, K. University Leuven and Janssen Pharmaceutica, B-2340, Beerse, (Belgium)

    W. Flameng, J. Vanhaecke, A. Van de Water & M. Suy

Authors
  1. W. Flameng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Xhonneux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Vanhaecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Van de Water
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Suy
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

In part supported by a grant from I.W.O.N.L.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flameng, W., Xhonneux, R., Vanhaecke, J. et al. Prevention of the “no reflow” phenomenon in the canine heart by mioflazine. Basic Res Cardiol 80, 27–36 (1985). https://doi.org/10.1007/BF01906741

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01906741

Key words

Search

Navigation